Immunocore Holdings plc (NASDAQ:IMCR) Receives Average Rating of “Moderate Buy” from Analysts

Immunocore Holdings plc (NASDAQ:IMCR) has been given an average recommendation of “Moderate Buy” by the thirteen ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $65.64.

IMCR has been the subject of a number of research reports. Mizuho cut shares of Immunocore from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $72.00 to $38.00 in a research report on Monday, November 11th. Guggenheim cut shares of Immunocore from a “buy” rating to a “neutral” rating in a research report on Monday, October 7th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Thursday, October 24th. UBS Group initiated coverage on shares of Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 target price for the company. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $35.00 price target (down from $74.00) on shares of Immunocore in a report on Friday.

Institutional Investors Weigh In On Immunocore

Institutional investors have recently bought and sold shares of the stock. Exchange Traded Concepts LLC grew its stake in Immunocore by 40.4% during the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after buying an additional 1,461 shares during the period. Connective Portfolio Management LLC purchased a new stake in Immunocore during the third quarter worth approximately $218,000. China Universal Asset Management Co. Ltd. grew its stake in Immunocore by 69.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after buying an additional 3,053 shares during the period. XTX Topco Ltd purchased a new stake in Immunocore during the second quarter worth approximately $303,000. Finally, Seven Eight Capital LP purchased a new stake in Immunocore during the second quarter worth approximately $434,000. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Stock Down 4.6 %

IMCR stock opened at $28.91 on Wednesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore has a one year low of $28.27 and a one year high of $76.98. The company has a fifty day moving average of $32.28 and a 200-day moving average of $35.21. The stock has a market capitalization of $1.45 billion, a PE ratio of -30.43 and a beta of 0.73.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm had revenue of $80.25 million during the quarter, compared to analysts’ expectations of $78.94 million. During the same quarter last year, the business earned ($0.59) earnings per share. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. As a group, analysts expect that Immunocore will post -0.94 EPS for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.